Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.5% – Here’s What Happened

Lisata Therapeutics, Inc. (NASDAQ:LSTA) traded down 3.5% during mid-day trading on Friday . The company traded as low as $1.05 and last traded at $1.09. Approximately 24,983 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 128,470 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

LSTA has been the subject of several recent research reports. Weiss Ratings raised shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a report on Monday, May 18th. Finally, HC Wainwright lowered shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Stock Performance

The company has a market cap of $9.82 million, a P/E ratio of -0.59 and a beta of 0.88. The firm has a 50 day moving average price of $2.64 and a 200-day moving average price of $3.63.

Institutional Investors Weigh In On Lisata Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cerity Partners LLC bought a new stake in Lisata Therapeutics during the second quarter worth approximately $32,000. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the third quarter valued at approximately $37,000. SOL Capital Management CO acquired a new stake in shares of Lisata Therapeutics in the first quarter worth $61,000. Ground Swell Capital LLC lifted its stake in shares of Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after buying an additional 15,213 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Lisata Therapeutics in the second quarter worth $157,000. 8.94% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.